Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity (Q40321504)

19 September 2017

title

Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity (English)

1 reference

19 September 2017

Sébastien Cornet

1

1 reference

19 September 2017

Isabelle Miconnet

2

1 reference

19 September 2017

Jeanne Menez

3

1 reference

19 September 2017

François Lemonnier

4

1 reference

19 September 2017

Kostas Kosmatopoulos

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

28 November 2005

1 reference

19 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 September 2017

volume

24

1 reference

19 September 2017

issue

12

1 reference

19 September 2017

page(s)

2102-2109

1 reference

Cancer immunotherapy: moving beyond current vaccines

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Human tumor antigens recognized by T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Hierarchy, tolerance, and dominance in the antitumor T-cell response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Induction of anti-self-immunity to cure cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Expression of MAGE genes in primary and metastatic cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

HER-2/neu signal transduction in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

T cell defined tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Prediction of proteasome cleavage motifs by neural networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

An algorithm for the prediction of proteasomal cleavages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

PAProC: a prediction algorithm for proteasomal cleavages available on the WWW.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

T cell fitness determined by signal strength

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.015

10.1016/J.VACCINE.2005.11.015

7 January 2021

Identifiers

DOI

1 reference

release_vzoq2isanbb7bkriu46qnlfuyu

19 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vzoq2isanbb7bkriu46qnlfuyu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference